{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red107\green107\blue106;
\red14\green86\blue140;
\red33\green33\blue33;
\red37\green37\blue37;
\red255\green255\blue102;
\red249\green250\blue251;
\red204\green204\blue204;
\red228\green231\blue232;
\red119\green119\blue119;
\red238\green238\blue238;
\red20\green93\blue164;
\red246\green246\blue246;
\red80\green80\blue80;
\red51\green51\blue51;
\red181\green79\blue104;
\red151\green151\blue151;
\red0\green114\blue54;
\red254\green254\blue0;
\red106\green144\blue39;
\red56\green124\blue43;
\red233\green233\blue233;
\red21\green137\blue21;
\red232\green233\blue232;
\red249\green249\blue249;
\red255\green248\blue96;
\red112\green112\blue112;
\red214\green9\blue9;
\red247\green247\blue247;
\red255\green194\blue211;
\red203\green203\blue203;
\red245\green245\blue245;
\red187\green187\blue187;
\red118\green118\blue118;
\red240\green240\blue240;
\red105\green105\blue105;
\red227\green227\blue227;
\red242\green242\blue242;
\red239\green122\blue2;
\red190\green190\blue252;
\red236\green236\blue236;
\red255\green255\blue204;
\red255\green204\blue0;
\red229\green243\blue255;
\red179\green218\blue255;
\red185\green185\blue185;
\red218\green218\blue218;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red188\green41\blue30;
\red190\green237\blue228;
\red255\green255\blue174;
\red102\green0\blue102;
\red61\green61\blue61;
\red214\green214\blue214;
\red102\green102\blue102;
\red240\green248\blue255;
\red127\green127\blue127;
\red183\green242\blue206;
\red204\green255\blue255;
\red182\green231\blue243;
\red71\green120\blue194;
\red153\green255\blue102;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 Source Sans Pro;}{
\f6 Courier New;}{
\f7 serif;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid1167370760\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid-1082781031}
}
{\*\listoverridetable
{\*\listoverride{\listid-1082781031\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Natural Alternatives International, Inc. v. Creative Compounds, LLC, 918 F.3d 1338 (2019)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_79}{\*\bkmkend co_document_79}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I35f48e50475611e98335c7ebe72735f9_Target}{\*\bkmkend I35f48e50475611e98335c7ebe72735f9_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_79}{\*\bkmkend co_readingModeKC_79}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_79}{\*\bkmkend co_readingModeCitatorFlag_79}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I35f48e50475611e98335c7ebe72735f9&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Yellow Flag - Negative Treatment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_79}{\*\bkmkend co_readingModeNegativeTreatment_79}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Distinguished by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/I72775400551111eb8cb3c4fde92c4669/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DI72775400551111eb8cb3c4fde92c4669%26ss%3D2047780027%26ds%3D2052751299%26origDocGuid%3DI35f48e50475611e98335c7ebe72735f9&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=5cd94d6206c547a5b78554264af3d4d5&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Mortgage Application Technologies, LLC v. MeridianLink, Inc.
}
{\b0 \cf20 \f2 \i0 \fs16 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Fed.Cir.(Cal.), 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
January 12, 2021
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
918 F.3d 1338
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States Court of Appeals, Federal Circuit.
\par 
}
}
}
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
NATURAL ALTERNATIVES INTERNATIONAL, INC., Plaintiff-Appellant
\par 
}
}
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
CREATIVE COMPOUNDS, LLC, Defendant-Appellee
\par 
}
}
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Does 1-100, Core Supplement Technologies, Inc., 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5061657104)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Honey Badger, LLC
}}}
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5067881983)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Myopharma, Inc.
}}}
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
, Defendants
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2018-1295
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Decided: March 15, 2019
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_79}{\*\bkmkend co_synopsis_79}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Patentee whose patents pertained to beta-alanine human nutritional supplements brought action against competitor, alleging, inter alia, violation of Lanham Act and patent infringement. The United States District Court for the Southern District of California, No. 3:16-cv-02146-H-AGS, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0136901901&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Marilyn L. Huff
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J., 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041948211&pubNum=0007903&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
258 F.Supp.3d 1170
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, held that patents were invalid, and granted judgment on the pleadings, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042525005&pubNum=0000999&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2017 WL 3877808
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Patentee appealed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holdings:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court of Appeals, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0368246101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moore
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, Circuit Judge, held that:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claims on method of treatment covering using existing natural product in unnatural quantities to alter patient\u8217\'3fs natural state, to treat patient with specific dosages outlined in patents, were directed to eligible subject matter;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
patentee plausibly stated that claims in patent regarding treatment method that relied on relationships between administration of beta-alanine and beta-alanylhistidine dipeptide synthesis contained transformative additional elements;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claims in patent directed to specific treatment formulations that incorporated beta-alanine as natural product, but that had different characteristics and that could be used in manner that beta-alanine as it appeared in nature could not, were directed to eligible subject matter;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
patentee plausibly stated that claims in patent directed to specific treatment formulations that incorporated beta-alanine, but that had different characteristics and that could be used in manner that beta-alanine as it appeared in nature could not, contained transformative additional elements; and
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claim directed to manufacture of non-natural human dietary supplement with certain characteristics was directed to eligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reversed and remanded.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0156955701&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reyna
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Circuit Judge, filed opinion concurring-in-part, dissenting-in-part.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1341_79}{\*\bkmkend co_pp_sp_506_1341_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1341
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 Appeal from the United States District Court for the Southern District of California in No. 3:16-cv-02146-H-AGS, Judge Marilyn L. Huff.
\par 
}
}
}
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_79}{\*\bkmkend co_attorneysAndLawFirms_79}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0329003301&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kevin M. Bell
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Porzio, Bromberg & Newman, PC, Washington, DC, argued for plaintiff-appellant. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0334411101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Scott A. M. Chambers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Billy Dell Chism, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0422814001&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Caroline Cook Maxwell
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0126971001&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Richard J. Oparil
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0513672701&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Matthew Zapadka
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Bass, Berry & Sims, PLC, Washington, DC.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0295876801&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kevin John O\u8217\'3fShea
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, O\u8217\'3fShea Law LLC, Jackson, MO, argued for defendant-appellee.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0428741901&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Melissa A. Brand
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Biotechnology Innovation Organization, Washington, DC, for amicus curiae Biotechnology Innovation Organization. Also represented by Hansjorg Sauer; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0105020101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Brian Paul Barrett
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Eli Lilly and Company, Indianapolis, IN.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0187063601&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kevin Edward Noonan
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, McDonnell, Boehnen, Hulbert & Berghoff, LLP, Chicago, IL, for amici curiae Christopher Michael Holman, David Lund, Adam Mossoff, Kristen J. Osenga, David O. Taylor. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0485240701&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Aaron Vincent Gin
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Before 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0368246101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moore
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0156955701&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reyna
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0126887301&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Wallach
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Circuit Judges.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_79}{\*\bkmkend co_opinion_79}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Opinion
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e477f339c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e477f339c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Opinion concurring-in-part and dissenting-in-part filed by Circuit Judge 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0156955701&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reyna
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb600 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0368246101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moore
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, Circuit Judge.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e6763429c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e6763429c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Natural Alternatives International, Inc., appeals a decision of the U.S. District Court for the Southern District of California granting Creative Compounds, LLC\u8217\'3fs motion for judgment on the pleadings that the asserted claims of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent Nos. 5,965,596
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
7,825,084
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
7,504,376
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035727267&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iee683580d88e11e48389be962897cf71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
8,993,610
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
8,470,865
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038574449&pubNum=0004073&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I578d0720f75111e5b10ddcfb6b98f38d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
RE45,947
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are not patent eligible. Because Creative Compounds has failed to demonstrate under Natural Alternatives\u8217\'3f proposed claim constructions that the claims are not patent eligible, we reverse and remand.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e6826919c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e6826919c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Background
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Natural Alternatives owns a number of patents that relate to dietary supplements containing beta-alanine and have substantially similar specifications. Beta-alanine is an amino acid. Together with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c963475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
histidine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, another amino acid, it can form dipeptides that are found in muscles. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
E.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f596 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 1:59\u8211\'3f64. The dipeptides are involved in the regulation of intra-cellular pH during muscle contraction and development of fatigue, and variations in dipeptide concentrations affect the anaerobic work capacity of individual athletes. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 4:58\u8211\'3f62, 5:1\u8211\'3f3. One of these dipeptides is carnosine, which contributes to hydronium ion buffering. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2:11\u8211\'3f13. During certain sustained exercise, hydronium ions and lactate can accumulate and severely reduce intracellular pH. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1:50\u8211\'3f54. The reduced pH interferes with the creatine-phosphorylcreatine system, a part of the process by which energy is generated in cells, particularly muscle cells. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1:31\u8211\'3f43, 1:54\u8211\'3f55. The claimed patents generally relate to the use of beta-alanine in a dietary supplement to \u8220\'3fincreas[e] the anaerobic working capacity of muscle and other tissue.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2:16\u8211\'3f18.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Natural Alternatives has asserted its patents in multiple suits in the Southern District of California. Creative Compounds 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1342_79}{\*\bkmkend co_pp_sp_506_1342_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1342
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 moved for judgment on the pleadings, which the district court granted. Applying the two-part test from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_217&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_217" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd. v. CLS Bank International
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. 208, 217, 134 S.Ct. 2347, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, it held all of the asserted claims were directed to patent ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and lacked an inventive concept sufficient to render them patent eligible. The district court granted judgment in favor of Creative Compounds, and Natural Alternatives timely appealed. We have jurisdiction under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1295&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_7b9b000044381" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 1295(a)(1)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e6a22619c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e6a22619c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Legal Standards
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the Patent Act provides that \u8220\'3f[w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The term \u8220\'3fprocess\u8221\'3f \u8220\'3fincludes a new use of a known process, machine, manufacture, composition of matter, or material.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS100&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 100(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Supreme Court has explained that under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, patent protection does not extend to the patent ineligible concepts of laws of nature, natural phenomena, and abstract ideas, which are \u8220\'3fbuilding blocks of human ingenuity.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_216&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_216" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. at 216\u8211\'3f17, 134 S.Ct. 2347
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We must therefore distinguish between claims to patent ineligible subject matter and those that \u8220\'3fintegrate the building blocks into something more.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 217, 134 S.Ct. 2347
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12047780027_79}{\*\bkmkend co_anchor_B12047780027_79}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In doing so, we first determine whether the claims at issue are \u8220\'3fdirected to\u8221\'3f a patent ineligible concept. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As the Supreme Court has cautioned, we must be careful in this analysis as \u8220\'3ftoo broad an interpretation of this exclusionary principle could eviscerate patent law. For all inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_71" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 71, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If we determine that the claims are directed to a patent ineligible concept, \u8220\'3fwe consider the elements of each claim both individually and \u8216\'3fas an ordered combination\u8217\'3f to determine whether additional elements \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent-eligible application,\u8221\'3f i.e., whether there is an \u8220\'3finventive concept.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_217&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_217" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. at 217, 134 S.Ct. 2347
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
quoting 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_78&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_78" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 78\u8211\'3f79, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22047780027_79}{\*\bkmkend co_anchor_B22047780027_79}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B32047780027_79}{\*\bkmkend co_anchor_B32047780027_79}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a question of law based on underlying facts that, ultimately, we review de novo. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2045179669&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1166&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1166" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
SAP Am. v. InvestPic, LLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 898 F.3d 1161, 1166 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. It may be resolved on a motion to dismiss where \u8220\'3fthere are no factual allegations that, taken as true, prevent resolving the eligibility question as a matter of law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043808569&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1125&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1125" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Aatrix Software, Inc. v. Green Shades Software, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 882 F.3d 1121, 1125 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e6ce1819c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e6ce1819c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Discussion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B42047780027_79}{\*\bkmkend co_anchor_B42047780027_79}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B52047780027_79}{\*\bkmkend co_anchor_B52047780027_79}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B62047780027_79}{\*\bkmkend co_anchor_B62047780027_79}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B72047780027_79}{\*\bkmkend co_anchor_B72047780027_79}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B82047780027_79}{\*\bkmkend co_anchor_B82047780027_79}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court held that the claims at issue are not patent eligible and dismissed. We review a district court\u8217\'3fs Rule 12(c) dismissal for judgment on the pleadings under the law of the regional circuit. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040226409&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1293&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1293" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Amdocs (Isr.) Ltd. v. Openet Telecom, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 841 F.3d 1288, 1293 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Ninth Circuit reviews a court\u8217\'3fs grant of judgment on the pleadings de novo. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043752652&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1083&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1083" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Newton v. Parker Drilling Mgmt. Servs., Ltd.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 881 F.3d 1078, 1083 (9th Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This analysis is \u8220\'3ffunctionally identical\u8221\'3f to the standard for deciding a motion to dismiss. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2024859050&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1055&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1055" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cafasso v. Gen. Dynamics C4 Sys., Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 637 F.3d 1047, 1055 n.4 (9th Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1989014572&pubNum=0000350&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_350_1192&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1192" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Dworkin v. Hustler Magazine Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 867 F.2d 1188, 1192 (9th Cir. 1989)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). In doing so, the court \u8220\'3finquire[s] 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1343_79}{\*\bkmkend co_pp_sp_506_1343_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1343
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 whether the complaint\u8217\'3fs factual allegations, together with all reasonable inferences, state a plausible claim for relief.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2024859050&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1055&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1055" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1055
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In the Ninth Circuit, a court deciding a motion under Rule 12 may consider \u8220\'3fmaterial which is properly submitted as part of the complaint,\u8221\'3f including documents that are not physically attached to the complaint, if their authenticity is not contested and the complaint necessarily relies on them, and it may take judicial notice of matters of public record. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001385224&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_688&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_688" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Lee v. City of L.A.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 250 F.3d 668, 688\u8211\'3f89 (9th Cir. 2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court stated that in performing its eligibility analysis, it accepted Natural Alternatives\u8217\'3f proposed claim constructions. J.A. 7 n.3. This was proper given the stage of the litigation. Applying the proposed claim constructions, we hold that the complaint\u8217\'3fs factual allegations, together with all reasonable inferences, plausibly establish the eligibility of the representative claims.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012047780027_ID0EPNBG_79}{\*\bkmkend co_fnRef_B00012047780027_ID0EPNBG_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e7100319c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e7100319c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
I.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Several of the asserted patents claim methods of treatment using beta-alanine (\u8220\'3fthe Method Claims\u8221\'3f). Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f596 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f865 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 have been treated as representative of the claims in those patents. Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f596 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recites:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A method of regulating hydronium ion concentrations in a human tissue comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
providing an amount of beta-alanine to blood or blood plasma 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
effective to increase beta-alanylhistidine dipeptide synthesis in the human tissue
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
exposing the tissue to the blood or blood plasma, whereby the concentration of beta-alanylhistidine is increased in the human tissue.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f865 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recites:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A method of increasing anaerobic working capacity in a human subject, the method comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
a) providing to the human subject an amount of an amino acid to blood or blood plasma 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
effective to increase beta-alanylhistidine dipeptide synthesis
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 in the tissue, wherein said amino acid is at least one of:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
i) beta-alanine that is not part of a dipeptide, polypeptide or oligopeptide;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1344_79}{\*\bkmkend co_pp_sp_506_1344_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1344
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 ii) an ester of beta-alanine that is not part of a dipeptide, polypeptide or oligopeptide; or
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
iii) an amide of beta-alanine that is not part of a dipeptide, polypeptide or oligopeptide; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
b) exposing the tissue to the blood or blood plasma, whereby the concentration of beta-alanylhistidine is increased in the tissue,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
wherein the amino acid is provided through a 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
dietary supplement
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Natural Alternatives\u8217\'3f proposed construction of the \u8220\'3feffective\u8221\'3f limitations is to \u8220\'3felevates beta-alanine above natural levels to cause an increase in the synthesis of beta-alanylhistidine dipeptide in the tissue.\u8221\'3f J.A. 579\u8211\'3f81. It defines \u8220\'3fdietary supplement\u8221\'3f as \u8220\'3fan addition to the human diet, which is not a natural or conventional food, which effectively increases athletic performance when administered to the human over a period of time.\u8221\'3f J.A. 581. It also defines \u8220\'3fincreasing anaerobic working capacity\u8221\'3f as \u8220\'3fincreasing the amount of work performed by a muscle under lactate producing conditions.\u8221\'3f J.A. 580.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court held both claims are directed to natural laws. It held claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f865 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to the natural law that \u8220\'3fingesting certain levels of beta-alanine, a natural substance, will increase the carnosine concentration in human tissue and, thereby, increase the anaerobic working capacity in a human.\u8221\'3f J.A. 22. It held claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f596 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to the natural law that \u8220\'3fingesting certain levels of beta-alanine, a natural substance, will increase the carnosine concentration in human tissue and, thereby, aid in regulating hydronium ion concentration in the tissue.\u8221\'3f J.A. 21. We do not agree.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Administering certain quantities of beta-alanine to a human subject alters that subject\u8217\'3fs natural state. Specifically, homeostasis is overcome, and the subject\u8217\'3fs body will produce greater levels of creatine. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f596 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 5:27\u8211\'3f
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This, in turn, results in specific physiological benefits for athletes engaged in certain intensive exercise. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f596 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 5:21\u8211\'3f23. The claims not only embody this discovery, they require that an infringer actually administer the dosage form claimed in the manner claimed, altering the athlete\u8217\'3fs physiology to provide the described benefits. These are treatment claims and as such they are patent eligible.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As we explained in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1134&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1134" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Ltd.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d 1117, 1134\u8211\'3f36 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, claims that are directed to particular methods of treatment are patent eligible. The claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 involved a method of treating patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that first required performing a genetic test to determine if a patient was a CYPD2D6 performer. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1121&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1121" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1121
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Based on the results of that test, a particular dose of iloperidone was selected and internally administered. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As a result, the risk of QTc prolongation, a dangerous side effect, was decreased. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1121&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1121" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1121 & n.2
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We held that the claims were not directed to a natural relationship between iloperidone, CYP2D6 metabolism, and QTc prolongation. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1134&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1134" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1134
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While we acknowledged that the inventors had recognized the underlying relationships, we explained that those were not what was claimed. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1135
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Instead, the claims were directed to a patent-eligible method of using iloperidone to treat 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3fa specific method of treatment for specific patients using a specific compound at specific doses to achieve a specific outcome.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1136&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1136" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1136
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Unlike the claims held ineligible in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which required only the observation of a natural law, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims required a doctor to affirmatively administer a drug to alter a patient\u8217\'3fs condition from 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1345_79}{\*\bkmkend co_pp_sp_506_1345_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1345
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 their natural state. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1135
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the discovery underlying the claims was that when blood levels were above a certain level harmful effects were more likely and when they were below another level the drug\u8217\'3fs beneficial effects were lost. Nothing in the claim required any application of that discovery beyond the \u8220\'3fsteps that must be taken in order to apply the laws in question.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_82&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_82" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 82, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The claims at issue in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 involved administering a prior art drug to a subject and determining the level of drug metabolite in that subject. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 74\u8211\'3f75, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The claims further provided that particular levels of measured metabolite indicated a need to increase or decrease the amount of drug subsequently administered to the subject. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 75, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The claims did not, however, require any actual action be taken based on the measured level of metabolite. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 75\u8211\'3f76, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The claim, therefore, \u8220\'3fwas not a treatment claim,\u8221\'3f because \u8220\'3fit was \u8216\'3fnot limited to instances in which the doctor actually decreases (or increases) the dosage level.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1136&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1136" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d at 1136
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_76&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_76" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 76, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). This was expressly recognized in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which distinguished the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claim from \u8220\'3fa typical patent on a new drug or 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
a new way of using an existing drug
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f because the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claim did not \u8220\'3fconfine [its] reach to particular applications\u8221\'3f of the natural laws relied upon. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_87&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_87" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
566 U.S. at 87, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added). Such claims rely on the relationship between the administration of the drug and the physiological effects in the patient. The fact that the human body responds to the treatment through biochemical processes does not convert the claim into an ineligible one. As we explained in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1049&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1049" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litigation Management Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042, 1049 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the \u8220\'3fnatural ability of the subject matter to 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
undergo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the process does not make the claim \u8216\'3fdirected to\u8217\'3f that natural ability.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B92047780027_79}{\*\bkmkend co_anchor_B92047780027_79}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Method Claims are directed to patent eligible new ways of using an existing product, beta-alanine, they are treatment claims. This falls clearly within the scope of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which allows for patents on \u8220\'3fany new and useful process,\u8221\'3f including \u8220\'3fa new use of a known ... composition of matter, or material.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS100&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f\u167\'3f 100(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As the Supreme Court explained in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, such patents on a new use of an existing drug are \u8220\'3ftypical.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_87&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_87" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
566 U.S. at 87, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
While the Method Claims have similarities to the claims found ineligible in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as they utilize an underlying natural law, this is not sufficient to establish that they are directed to that law. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Court held the claims did not do significantly more than simply describe the natural \u8220\'3frelationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of a thiopurine drug will prove ineffective or cause harm.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 77, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Method Claims similarly rely on the relationships between the administration of beta-alanine and beta-alanylhistidine dipeptide synthesis, but under Natural Alternatives\u8217\'3f constructions, the Method Claims require specific steps be taken in order to bring about a change in a subject, altering the subject\u8217\'3fs natural state. Unlike the claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Method Claims at issue are treatment claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Like the claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Method Claims contain specific elements that clearly establish they are doing more than simply reciting a natural law. Like the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims, which specify a patient population to be treated, the Method Claims specify particular results to be obtained by practicing the method. Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f596 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to a \u8220\'3fmethod of regulating 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1346_79}{\*\bkmkend co_pp_sp_506_1346_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1346
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 hydronium ion concentrations in a human tissue,\u8221\'3f and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f865 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to a \u8220\'3fmethod of increasing anaerobic working capacity in a human subject.\u8221\'3f Similarly, both the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims and the Method Claims specify a compound to be administered to achieve the claimed result. Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f596 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 achieves the result through the administration of the specific compound beta-alanine, and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f865 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 requires use of one of the three specified forms of beta-alanine. The claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 further specified the dosages of the compound to be administered. The Method Claims likewise contain a dosage limitation by virtue of the \u8220\'3feffective\u8221\'3f limitation. As we looked to the specification in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to determine the significance of the dosing ranges, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
887 F.3d at 1135
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, here, the specification provides a method for calculating dosage based on a subject\u8217\'3fs weight, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f596 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 5:48\u8211\'3f50. This goes far beyond merely stating a law of nature, and instead sets forth a particular method of treatment.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, the fact that the active ingredient in the supplement is a molecule that occurs in nature and is consumed as part of the human diet also does not alter our analysis.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022047780027_ID0ELTAI_79}{\*\bkmkend co_fnRef_B00022047780027_ID0ELTAI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Creative Compounds argues that, if it were discovered that beta-alanine or another natural compound can be used to treat or cure Alzheimer\u8217\'3fs or some other disease, the method for doing so would not be patent eligible. Appellee Br. 28\u8211\'3f29; Oral Arg. at 15:10\u8211\'3f
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. That is not the case before us. That flies in the face of the Patent Act, which expressly permits patenting a new use of an existing product. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS100&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f\u167\'3f 100(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Supreme Court has also rejected the idea that claims to methods making use of natural products are equivalent to claims to the natural products themselves. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_595&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_595" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ass\u8217\'3fn for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. 576, 595, 133 S.Ct. 2107, 186 L.Ed.2d 124 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (distinguishing between method claims for manipulating genes and claims to the genes); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_130&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_130" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Funk Brothers Seed Co. v. Kalo Inoculant Co.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 333 U.S. 127, 130, 68 S.Ct. 440, 92 L.Ed. 588 (1948)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fWe do not have presented the question whether the methods of selecting and testing the non-inhibitive strains are patentable. We have here only product claims.\u8221\'3f). Moreover, while beta-alanine may exist in nature, Natural Alternatives has argued that the quantities being administered do not, and that the claimed consumption greatly exceeds natural levels. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 580\u8211\'3f81 (providing a construction of the \u8220\'3feffective\u8221\'3f limitation in each of the Method Claims to mean \u8220\'3felevates beta-alanine 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
above natural levels
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to cause an increase in the synthesis of beta-alanylhistidine in the tissue\u8221\'3f (emphasis added)).
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032047780027_ID0EOWAI_79}{\*\bkmkend co_fnRef_B00032047780027_ID0EOWAI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Method Claims at issue are treatment claims. They cover using a natural product in unnatural quantities to alter a patient\u8217\'3fs natural state, to treat a patient with specific dosages outlined in the patents. We hold, therefore, that the Method 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1347_79}{\*\bkmkend co_pp_sp_506_1347_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1347
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Claims are not directed to ineligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B102047780027_79}{\*\bkmkend co_anchor_B102047780027_79}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B112047780027_79}{\*\bkmkend co_anchor_B112047780027_79}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, at step two, factual impediments exist to resolving the case at this stage. Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f865 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 requires \u8220\'3fthe amino acid is provided through a dietary supplement,\u8221\'3f with the dietary supplement limitation construed as \u8220\'3fan addition to the human diet, which is not a natural or 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
conventional
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 food.\u8221\'3f J.A. 581 (emphasis added). Creative Compounds argues that the \u8220\'3finventors admitted in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f865 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and all of the patents-on-appeal, that placing a natural substance into a dietary supplement for administration to a human, in order to increase the function of tissues is a conventional, well-known activity.\u8221\'3f Appellee Br. 37 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f865 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 1:41\u8211\'3f44). The language it cites, however, does not stand for that proposition. Instead, the patent states \u8220\'3f[n]atural food supplements are typically designed to compensate for reduced levels of nutrients in the modern human and animal diet. In particular, useful supplements increase the function of tissues when consumed.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f865 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 1:41\u8211\'3f44. At most, this language shows that the prior art contained food supplements containing natural products, and typically those were used to compensate for reduced levels of nutrients. It does not establish that the dietary supplement in the claims, which provides a dose well in excess of the normal levels of beta-alanine, would have been well-understood, routine, and conventional. While a fact-finder may ultimately determine that the dietary supplement limitation was well-understood, routine, and conventional, absent a clear statement to that effect in the specification, complaint, or other material properly before the court, when disputed such a determination may not be made on a motion for judgment on the pleadings.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Under Natural Alternatives\u8217\'3f proposed claim constructions, the Method Claims are not directed to an exception to 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 under the first step of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test. Therefore, judgment on the pleadings was inappropriate.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e81f0219c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e81f0219c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
II.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B122047780027_79}{\*\bkmkend co_anchor_B122047780027_79}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court also considered the patent eligibility of a number of claims to dietary supplements (\u8220\'3fthe Product Claims\u8221\'3f). The parties and the district court treated claim 6 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f376 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as representative of the claims in those patents. Claim 6 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f376 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 depends on claims 1 and 5. In its opinion, the district court also held representative claim 34 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038574449&pubNum=0004073&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I578d0720f75111e5b10ddcfb6b98f38d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f947 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ineligible. Representative claim 34 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038574449&pubNum=0004073&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I578d0720f75111e5b10ddcfb6b98f38d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f947 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recites:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
34. A human dietary supplement for increasing human muscle tissue strength comprising a mixture of creatine, a carbohydrate and free amino acid beta-alanine that is not part of a dipeptide, polypeptide or an oligopeptide, wherein the human dietary supplement does not contain a free amino acid 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=bdrug&entityId=I396eb006475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
L-histidine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, wherein the free amino acid beta-alanine is in an amount that is from 0.4 g to 16.0 g per daily dose, wherein the amount increases the muscle tissue strength in the human, and wherein the human dietary supplement is formulated for one or more doses per day for at least 14 days.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Although Natural Alternatives argued that claim 34 is eligible as it is a treatment claim with a very specific dosing regimen contained within the claim itself, at oral argument Natural Alternatives acknowledged that this 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1348_79}{\*\bkmkend co_pp_sp_506_1348_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1348
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent was not asserted against Creative Compounds. Oral Arg. 0:52\u8211\'3f1:20. Though rendered ineligible in the same district court opinion as the other patents at issue in this appeal, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038574449&pubNum=0004073&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I578d0720f75111e5b10ddcfb6b98f38d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f947 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was not asserted against Creative Compounds.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042047780027_ID0EECBI_79}{\*\bkmkend co_fnRef_B00042047780027_ID0EECBI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Claims not asserted in this litigation against this appellee, Creative Compounds, are not properly before this court in this appeal. This does not prejudice the patentee\u8217\'3fs ability to defend the eligibility of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038574449&pubNum=0004073&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I578d0720f75111e5b10ddcfb6b98f38d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f947 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in future proceedings.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Turning to the Product Claims before us, claim 6 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f376 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 depends on claims 1 and 5.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A composition, comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
glycine
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
a) an amino acid selected from the group consisting of a beta-alanine, an ester of a beta-alanine, and an amide of a beta-alanine, or
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
b) a di-peptide selected from the group consisting of a beta-alanine di-peptide and a beta-alanylhistidine di-peptide.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
5. The composition of claim 1, wherein the composition is a dietary supplement or a sports drink.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
6. The composition of claim 5, wherein the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
dietary supplement
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 or sports drink is a supplement for humans.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recites:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. A human 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
dietary supplement
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, comprising a beta-alanine in a unit dosage of between about 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
0.4 grams to 16 grams
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, wherein the supplement provides a unit dosage of beta-alanine.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Natural Alternatives proposed construing \u8220\'3fdietary supplement\u8221\'3f in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f376 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and \u8220\'3fhuman dietary supplement\u8221\'3f in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to mean \u8220\'3fan addition to the human diet, which is not a natural or conventional food, which effectively increases athletic performance and is manufactured to be used over a period of time.\u8221\'3f J.A. 572, 574.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court held that the Product Claims are directed to ineligible subject matter. It held claim 6 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f376 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to the natural phenomena of beta-alanine and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to the natural phenomenon of beta-alanine. We do not agree.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B132047780027_79}{\*\bkmkend co_anchor_B132047780027_79}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Although beta-alanine is a natural product, the Product Claims are not directed to beta-alanine. A claim to a manufacture or composition of matter made from a natural product is not directed to the natural product where it has different characteristics and \u8220\'3fthe potential for significant utility.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_310&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_310" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Chakrabarty
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 447 U.S. 303, 310, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Just as the Method Claims are directed to specific methods of treatment that employ a natural law, the Product Claims are directed to specific treatment formulations that incorporate natural products, but they have different characteristics and can be used in a manner that beta-alanine as it appears in nature cannot.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In the Product Claims, beta-alanine and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are incorporated into particular dosage forms. Claim 6 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f376 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to a \u8220\'3fdietary supplement or sports drink\u8221\'3f that uses a combination of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and one of the specified forms of beta-alanine. Under Natural Alternatives\u8217\'3f claim constructions, the quantity of beta-alanine must be sufficient to \u8220\'3feffectively increase[ ] athletic performance,\u8221\'3f and the specification provides a method for determining such an amount. Similarly, the \u8220\'3fdietary supplement\u8221\'3f in claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 uses the product beta-alanine at a dosage of \u8220\'3fbetween about 0.4 grams to 16 grams\u8221\'3f to \u8220\'3feffectively increase[ ] athletic performance.\u8221\'3f In each case, the natural 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1349_79}{\*\bkmkend co_pp_sp_506_1349_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1349
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 products have been isolated and then incorporated into a dosage form with particular characteristics. At this stage in the litigation, it has been sufficiently alleged that these characteristics provide significant utility, as the claimed dosage forms can be used to increase athletic performance in a way that naturally occurring beta-alanine cannot. Accordingly, neither claim is directed to ineligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, even though claim 6 contains a combination of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and beta-alanine, both of which are natural products, that is not necessarily sufficient to establish that the claimed combination is \u8220\'3fdirected to\u8221\'3f ineligible subject matter. The Court\u8217\'3fs decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Funk Brothers
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not stand for the proposition that any combination of ineligible subject matter is itself ineligible. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Funk Brothers
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Court held that claims to a mixture of two naturally occurring bacteria were not patent eligible where each bacteria species in the claimed combination \u8220\'3fha[d] the same effect it always had,\u8221\'3f and the \u8220\'3fcombination of species produce[d] ... no enlargement of the range of their utility.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_780_131&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_131" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
333 U.S. at 131, 68 S.Ct. 440
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The combination of the bacteria into the same package did \u8220\'3fnot improve in any way their natural function.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Here, as Creative Compounds\u8217\'3f counsel acknowledged at oral argument, the record indicates that the claimed combination of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and beta-alanine could have synergistic effects allowing for outcomes that the individual components could not have. Oral Arg. 24:45\u8211\'3f51, 28:00\u8211\'3f29:30. Given that this is the pleading stage, we would have to accept this statement as true even if it were just an allegation in the pleadings. Instead, what we have goes far beyond that, including a statement in an article attached to an expert report explaining that \u8220\'3fone of insulin\u8217\'3fs effects is to increase amino acid (such as beta-alanine) into our cells,\u8221\'3f J.A. 1063, a statement in the specification that \u8220\'3f[i]t may be that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 enhances 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2808879475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
insulin sensitivity
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f376 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 6:3\u8211\'3f5, and an expert declaration explaining that direct supplementation of a different amino acid had no effect unless \u8220\'3fco-supplemented with glucose or other compounds increasing the concentration of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c670878475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
insulin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in circulation,\u8221\'3f J.A. 1132. All of these suggest that when combined the beta-alanine and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 have effects that are greater than the sum of the parts. At a minimum, there are sufficient factual allegations to render judgment on the pleadings inappropriate. Accordingly, given the factual allegations, these claims would still survive a motion for judgment on the pleadings at the first step of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B142047780027_79}{\*\bkmkend co_anchor_B142047780027_79}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Finally, even if the Product Claims were directed to ineligible subject matter, judgment on the pleadings would still be inappropriate under step two. Like claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f865 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Product Claims contain a dietary supplement limitation, with the same proposed construction. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 572, 574. As we explained with regard to the Method Claims, the specification does not contain language supporting the idea that this limitation was well-understood, routine, and conventional. The language in the specification does not support this proposition, and patentee\u8217\'3fs claim construction contradicts Creative Compounds\u8217\'3f position, so such a determination may not be made on a motion for judgment on the pleadings.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e8e25219c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e8e25219c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
III.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B152047780027_79}{\*\bkmkend co_anchor_B152047780027_79}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The parties and the district court have treated claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035727267&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iee683580d88e11e48389be962897cf71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as representative of the claims in that patent (\u8220\'3fthe Manufacturing Claims\u8221\'3f). It recites:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. Use of beta-alanine in manufacturing a human dietary supplement for oral consumption;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1350_79}{\*\bkmkend co_pp_sp_506_1350_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1350
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 supplying the beta-alanine, which is not part of a dipeptide, polypeptide or oligopeptide, as a single ingredient in a manufacturing step of the human 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
dietary supplement
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 or
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
mixing the beta-alanine, which is not part of a dipeptide, polypeptide or oligopeptide, in combination with at least one other ingredient for the manufacture of the human 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
dietary supplement
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
whereby the manufactured human dietary supplement is for oral consumption of the human dietary supplement in doses over a period of time increases beta-alanyl 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c963475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
histidine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 levels in muscle tissue sufficient to delay the onset of fatigue in the human.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Natural Alternatives proposed construing \u8220\'3f[u]se of beta-alanine in manufacturing a human dietary supplement\u8221\'3f to mean \u8220\'3fmaking an addition to the human diet using beta-alanine, which is not a natural or conventional food, to be administered over a period of time and that effectively increases athletic performance.\u8221\'3f J.A. 574. It proposed construing \u8220\'3fsupplying the beta-alanine, which is not part of a dipeptide, polypeptide or oligopeptide, as a single ingredient in a manufacturing step of the human dietary supplement\u8221\'3f to mean \u8220\'3fproviding the free amino acid beta-alanine, an ester of beta-alanine or an amide of beta-alanine in a step of making an addition to the human diet using beta-alanine as the only active ingredient, which is not a natural or conventional food, which effectively increases athletic performance when administered to a human over a period of time.\u8221\'3f J.A. 575. It proposed construing \u8220\'3fmixing the beta-alanine, which is not part of a dipeptide, polypeptide or oligopeptide, in combination with at least one other ingredient for the manufacture of the human dietary supplement\u8221\'3f to mean \u8220\'3fmaking an addition to the human diet, which is not a natural or conventional food, and which effectively increases athletic performance when administered to a human over a period of time, using the free amino acid beta-alanine, an ester of beta-alanine or an amide of beta-alanine and at least one other ingredient.\u8221\'3f J.A. 575.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court held claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035727267&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iee683580d88e11e48389be962897cf71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to \u8220\'3fthe natural phenomenon beta alanine and the natural law that ingesting certain levels of beta-alanine will increase the carnosine concentration in human tissue.\u8221\'3f J.A. 24. We do not agree. The Manufacturing Claims are not directed to the natural law or product of nature, but instead are an application of the law and new use of that product. Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035727267&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iee683580d88e11e48389be962897cf71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is even further removed from the natural law and product of nature at issue in the Method Claims and Product Claims, respectively. It is directed to the manufacture of a human dietary supplement with certain characteristics. The supplement is not a product of nature and the use of the supplement to achieve a given result is not directed to a law of nature. We do not see, therefore, how a claim to the manufacture of a non-natural supplement would be directed to the law of nature or natural product.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e9159719c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e9159719c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Conclusion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The claims at issue are not directed to ineligible subject matter under step one of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test. We live in the natural world, and all inventions are constrained by the laws of nature. As the Supreme Court has warned, we must be careful not to overly abstract claims when performing the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis. For the foregoing reasons, we reverse the district court\u8217\'3fs decision that the claims are directed to ineligible subject matter, and we remand for further proceedings consistent with this opinion.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
REVERSED AND REMANDED
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_cipdip_opinion_79}{\*\bkmkend co_cipdip_opinion_79}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e926ae19c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e926ae19c4411ea8137f56d2b932}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0156955701&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reyna
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, Circuit Judge, concurring-in-part, dissenting-in-part.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e926ae19c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e926ae19c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1351_79}{\*\bkmkend co_pp_sp_506_1351_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1351
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The majority reverses the district court\u8217\'3fs grant of Creative Compounds\u8217\'3f motion for judgment on the pleadings under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which alleged that the asserted patents claim patent ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and remands the case for further proceedings. I dissent from my colleagues\u8217\'3f broad stroke of eligibility, primarily because I conclude that the majority\u8217\'3fs 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis relies on an erroneous claim construction. I concur, however, in the result reached by the majority to remand for further proceedings, which I expect permits the district court to revisit the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 question under a proper claim construction.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00052047780027_ID0EZ5BI_79}{\*\bkmkend co_fnRef_B00052047780027_ID0EZ5BI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00052047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e93a3619c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e93a3619c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6e93a3619c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6e93a3619c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa400 \sb600 
Discussion
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In construing claims, we give words the ordinary and customary meaning that the term would have to a person of ordinary skill in the art. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006931523&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1312&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1312" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Phillips v. AWH Corp.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 415 F.3d 1303, 1312 (Fed. Cir. 2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (en banc). In some cases, the ordinary meaning \u8220\'3fmay be readily apparent even to lay judges, and claim construction in such cases involves little more than the application of the widely accepted meaning of commonly understood words.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006931523&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1314&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1314" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1314
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This is such a case. For example, applying ordinary and customary meaning to the terms of claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, I would conclude as a matter of law that the claim is ineligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recites:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A human dietary supplement, comprising a beta-alanine in a unit dosage of between about 0.4 grams to 16 grams, wherein the supplement provides a unit dosage of beta-alanine.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 22 ll. 26\u8211\'3f29. Claim 1 is directed to what is undisputedly a naturally occurring substance, beta-alanine. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; Appellant Br. 4. This natural substance is applied by wholly conventional and natural means, adding it to a human\u8217\'3fs diet. Claim 1 discloses nothing else. In particular, the claim discloses no basis to argue that the claimed beta-alanine is transformed into something other than beta-alanine. Claim 1, therefore, recites patent ineligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The majority concludes that claim 1 is patent eligible. My main concern with its analysis is that it relies on a claim construction that improperly imports limitations into the claims and is contradicted by the written description. This may be an unavoidable result given the lack of claim construction in this case.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Natural Alternatives argued that the district court should construe the claims before resolving the motion for judgment on the pleadings. Creative Compounds asserted that, for purposes of the motion, the claims were ineligible both under its proposed construction and Natural Alternatives\u8217\'3f proposed construction.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court did not construe the claims, nor did it conclusively adopt either party\u8217\'3fs proposed claim construction. Instead, the court determined that, for purposes of the motion, it would review the claims under Natural Alternatives\u8217\'3f proposed claim construction, an approach that, in the district court\u8217\'3fs view, would obviate the need to defer deciding the 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1352_79}{\*\bkmkend co_pp_sp_506_1352_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1352
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion until after it conducted claim construction.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00062047780027_ID0ELGCI_79}{\*\bkmkend co_fnRef_B00062047780027_ID0ELGCI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00062047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
On appeal, Natural Alternatives argues that the district court ignored its proposed claim construction. Appellant Br. 19\u8211\'3f20. Natural Alternatives asserts that we should adopt its proposed construction and \u8220\'3fremand the case back to the District Court to engage in the proper procedure directed by 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Markman
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f Appellant Br. 2.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As to claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Natural Alternatives proposed the following claim construction to the district court:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(1) \u8220\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
human dietary supplement
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
\u8221\'3f be construed as \u8220\'3fan addition to the human diet, ingested as a pill, capsule, powder or liquid, which is not a natural or conventional food, meat or food flavoring or extract, or pharmaceutical product which effectively increases the function of a tissue when administered to the human over a period of time\u8221\'3f J.A. 14 n.8.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(2) \u8220\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
dietary supplement
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
\u8221\'3f be construed as \u8220\'3fan addition to the human diet, which is not a natural or conventional food, which effectively increases athletic performance and is manufactured to be used over a period of time.\u8221\'3f J.A. 14 n.8.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Creative Compounds proposed that \u8220\'3fdietary supplement\u8221\'3f be construed as:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
\u8220\'3fAn ingredient such as a vitamin, mineral, herb, amino acid, concentrate, or extract intended for ingestion, which adds further nutritional value to the diet by increasing tissue function.\u8221\'3f J.A. 586.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I find that Natural Alternatives\u8217\'3f construction of \u8220\'3fhuman dietary supplement\u8221\'3f and \u8220\'3fdietary supplement\u8221\'3f improperly imports limitations into the claims, incorporates a definition that is contrary to the plain meaning of the terms, and is flawed because it is contradicted by the written description.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For example, the construction imports the limitation that beta-alanine \u8220\'3feffectively increases the function of a tissue when administered to the human over a period of time.\u8221\'3f
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00072047780027_ID0EDMCI_79}{\*\bkmkend co_fnRef_B00072047780027_ID0EDMCI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00072047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 This limitation is not disclosed in the plain language of the claims and is only present by virtue of the proposed claim construction.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00082047780027_ID0ENMCI_79}{\*\bkmkend co_fnRef_B00082047780027_ID0ENMCI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00082047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1353_79}{\*\bkmkend co_pp_sp_506_1353_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1353
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Natural Alternatives\u8217\'3f proposed construction are also contradicted by the written description. For example, the proposed construction of \u8220\'3fhuman dietary supplement\u8221\'3f limits the claim in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to dietary supplements that are: (1) ingested in pill, capsule, powder, or liquid form; (2) not meat or food flavoring or extract, or a pharmaceutical product; (3) effective to increase the function of tissues over time; and (4) not natural or conventional food. Appellant Br. 20; J.A. 14 n.8. Yet the specification notes that \u8220\'3f[t]he compositions of the invention can be used for the preparation of a dietary supplement (including, e.g., drinks, gels, foods) or pharmaceutical compositions for humans or animals.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f084 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 5 ll. 13\u8211\'3f16. On the one hand, the construction excludes pharmaceutical products and foods, while on the other hand, the specification expressly includes foods within the definition of \u8220\'3fdietary supplement\u8221\'3f and expands the scope of the invention to include \u8220\'3fpharmaceutical compositions\u8221\'3f for humans or animals.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Interestingly, the District of Delaware, in evaluating a related patent, declined to construe \u8220\'3fdietary supplement,\u8221\'3f holding that the term was not a limitation. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Natural Alternatives Int\u8217\'3fl Inc. v. Vital Pharm. Inc.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 1:09-CV-00626, Dkt. No. 125 at 2 (D. Del. May 31, 2011) (\u8220\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Delaware Order
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f). The court noted that \u8220\'3fdietary supplement\u8221\'3f appeared only in the preamble of the claims and that the specifications did not demonstrate that the term was a necessary aspect of the invention.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00092047780027_ID0ERSCI_79}{\*\bkmkend co_fnRef_B00092047780027_ID0ERSCI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00092047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Natural Alternatives\u8217\'3f construction also defines \u8220\'3fhuman dietary supplement\u8221\'3f to \u8220\'3feffectively increase[ ]\u8221\'3f the function of a tissue over time.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00102047780027_ID0EJYCI_79}{\*\bkmkend co_fnRef_B00102047780027_ID0EJYCI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00102047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
6
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 14 n.8. This definition is contrary to the plain meaning of the term: \u8220\'3fa product taken orally that contains one or more ingredients which are intended to supplement one\u8217\'3fs diet and are not considered food.\u8221\'3f
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00112047780027_ID0E1YCI_79}{\*\bkmkend co_fnRef_B00112047780027_ID0E1YCI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00112047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
7
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Nor is this a case where 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1354_79}{\*\bkmkend co_pp_sp_506_1354_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1354
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the patentee has acted as its own lexicographer. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2026961295&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1365&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1365" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Thorner v. Sony Computer Entm\u8217\'3ft Am. LLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 669 F.3d 1362, 1365 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. To do so, \u8220\'3fa patentee must \u8216\'3fclearly set forth a definition of the disputed claim term\u8217\'3f other than its plain and ordinary meaning.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2026961295&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002284108&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1366&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1366" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CCS Fitness, Inc. v. Brunswick Corp.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 288 F.3d 1359, 1366 (Fed. Cir. 2002)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Nowhere does the patentee set forth such a definition.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00122047780027_ID0EC2CI_79}{\*\bkmkend co_fnRef_B00122047780027_ID0EC2CI_79}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00122047780027_79" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This court is hesitant to construe claims for the first time on appeal. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028412867&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1368&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1368" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Meyer Intellectual Props. Ltd. v. Bodum, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 690 F.3d 1354, 1368 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This tendency reflects a concern to avoid conflating de novo review with an independent analysis in the first instance. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019482888&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Wavetronix LLC v. EIS Elec. Integrated Sys.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 F.3d 1343, 1355 (Fed. Cir. 2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (noting this court\u8217\'3fs review of claim construction without deference is not an independent analysis in the first instance (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006439244&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1371&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1371" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nazomi Commc\u8217\'3fns, Inc. v. Arm Holdings, PLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 403 F.3d 1364, 1371 (Fed. Cir. 2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)). Construing claims on appeal, however, is proper under limited circumstances, particularly when the record is sufficiently developed to enable construction. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See e.g., 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028412867&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1369&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1369" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Meyer
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 690 F.3d at 1369
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019482888&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Wavetronix
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 F.3d at 1355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. I do not see such a record in this case. Apparently, the majority agrees because it too did not construe the claims, but rather choose to rely on the construction proposed by Natural Alternatives.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
If anything, this appeal was pre-ordained to result in a remand. The district court decided the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion at the pleading stage while acknowledging that it could defer its decision until after it conducted claim construction. On appeal, Natural Alternatives argues that the district court erred when it decided not to conduct claim construction before deciding the motion. The majority remands to the district court for further proceedings, which I take to mean could include a formal claim construction and a potential revisit of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issue.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I would remand because I believe the district court and the majority relied on an erroneous claim construction. So, the question is whether anything meaningful has been achieved in these circumstances. This case, and the general development of the law concerning 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis at the pleading stage, causes me to ask whether the time has come for this court to reconsider whether a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion based on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 should be decided before claim construction. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028287013&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1273&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1273" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bancorp Servs., L.L.C. v. Sun Life Assur. Co. of Canada (U.S.)
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 687 F.3d 1266, 1273\u8211\'3f74 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[I]t will ordinarily be desirable\u8212\'3fand often necessary\u8212\'3fto resolve claim construction disputes prior to a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis, for the determination of patent eligibility requires a full understanding of the basic character of the claimed subject matter.\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see e.g., 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034284637&pubNum=0007903&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_7903_835&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_835" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Loyalty Conversion Sys. Corp. v. Am. Airlines, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 66 F.Supp.3d 829, 835 (E.D. Tex. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Bryson, J.) (\u8220\'3f[T]he Court has waited until after the claim construction hearing in this case to rule on the [ 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1355_79}{\*\bkmkend co_pp_sp_506_1355_79}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1355
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion] in order to ensure that there are no issues of claim construction that would affect the Court\u8217\'3fs legal analysis of the patentability issue.\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039604423&pubNum=0000999&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Presqriber, LLC v. AO Capital Partners LLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 6:14-CV-440, 2015 WL 11578559, at *6 (E.D. Tex. Mar. 31, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (denying 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion without prejudice to conduct claim construction and obtain a full understanding of the claimed invention relevant to a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6eb227e19c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6eb227e19c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6eb227e19c4411ea8137f56d2b932}{\*\bkmkend co_anchor_I6eb227e19c4411ea8137f56d2b932}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa400 \sb600 
Conclusion
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
On the basis set forth above, I concur-in-part and dissent-in-part.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_79}{\*\bkmkend co_allCitations_79}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
918 F.3d 1338
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012047780027_79}{\*\bkmkend co_footnote_B00012047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012047780027_ID0EPNBG_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Though the dissent suggests disagreement with those constructions, we note that neither party argued for a different construction on appeal. The dissent\u8217\'3fs primary criticism is that the \u8220\'3feffective\u8221\'3f limitation \u8220\'3fis not disclosed in the plain language of the claims and is only present by virtue of the proposed claim construction.\u8221\'3f Dissent at 1352. Respectfully, this is not factually accurate as nearly all of the claims of four of the patents at issue contain express limitations requiring effectiveness. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f865 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 22:56\u8211\'3f23:29 (all claims require the amount administered be \u8220\'3feffective to increase beta-alanylhistidine dipeptide synthesis in the tissue\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999385326&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I5911c3e072e611d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f596 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 14:66\u8211\'3f15:6 (all claims require the amount administered be \u8220\'3feffective to increase beta-alanylhistidine dipeptide synthesis in the tissue\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f084 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 22:57\u8211\'3f64, 23:1\u8211\'3f24:3 (claims 13\u8211\'3f14 and 16\u8211\'3f18 require the claimed method \u8220\'3fincrease beta-alanylhistidine dipeptide synthesis in a tissue\u8221\'3f and \u8220\'3fthe anaerobic working capacity of the tissue is increased\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035727267&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iee683580d88e11e48389be962897cf71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f610 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 22:24\u8211\'3f23:5 (all claims require the supplement \u8220\'3fincrease[ ] beta-alanyl 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c963475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
histidine
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 levels in muscle tissue sufficient to delay the onset of fatigue in the human\u8221\'3f). The dissent also suggests the \u8220\'3fdietary supplement\u8221\'3f limitation may not be a limitation because it only appears in the preamble of the claims. Dissent at 1353. Again, that is not correct with regard to the claims at issue, many of which expressly include the dietary supplement limitation in the body. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f865 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 22:56\u8211\'3f23:29 (all claims); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035727267&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iee683580d88e11e48389be962897cf71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f610 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 22:24\u8211\'3f23:5 (all claims). In other claims, the \u8220\'3fdietary supplement\u8221\'3f language in the preamble provides a clear antecedent basis for language in the body of the claims. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f084 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 22:25\u8211\'3f38 (claims 1\u8211\'3f4).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022047780027_79}{\*\bkmkend co_footnote_B00022047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022047780027_ID0ELTAI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The U.S. Patent and Trademark Office has adopted guidance on how examiners should determine whether a claim is eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf20 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf20 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and provided examples of eligible and ineligible claims. Under these guidelines, a claim to a practical application of a natural product to treat a particular disease is patent eligible. The parties dispute the persuasiveness of this document and the weight we should afford it under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1944117044&pubNum=0000708&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Skidmore v. Swift & Co.
}
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 323 U.S. 134, 65 S.Ct. 161, 89 L.Ed. 124 (1944)
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. The issue before us is a matter of law and the result is clear, thus this is not a case in which 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1944117044&pubNum=0000780&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Skidmore
}
}\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 deference would affect the outcome.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032047780027_79}{\*\bkmkend co_footnote_B00032047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032047780027_ID0EOWAI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Indeed, the record contains an expert declaration stating that \u8220\'3fone 3.2 gram daily supplement of beta-alanine is the equivalent to eating at least 109 Big Macs per day.\u8221\'3f J.A. 914.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042047780027_79}{\*\bkmkend co_footnote_B00042047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042047780027_ID0EECBI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038574449&pubNum=0004073&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I578d0720f75111e5b10ddcfb6b98f38d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f947 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 was asserted in a related litigation against Hi-Tech Pharmaceuticals, Inc. At the time of oral argument, that case was stayed. That case against that defendant is not part of the present appeal.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00052047780027_79}{\*\bkmkend co_footnote_B00052047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00052047780027_ID0EZ5BI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2015665918&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1362&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1362" }{\fldrslt 
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
O2 Micro Int\u8217\'3fl Ltd. v. Beyond Innovation Tech. Co.
}
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 521 F.3d 1351, 1362\u8211\'3f63 (Fed. Cir. 2008)
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fWhen the parties present a fundamental dispute regarding the scope of a claim term, it is the court\u8217\'3fs duty to resolve it. Because we determine that the district court is in the best position to determine the proper construction of this claim term in the first instance, we remand for further proceedings consistent with this opinion.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00062047780027_79}{\*\bkmkend co_footnote_B00062047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00062047780027_ID0ELGCI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The majority points out that neither party argued for a different construction on appeal. But I believe that is only a reflection of the procedural posture of this case. This appeal concerns the district court\u8217\'3fs grant of a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Rule 12(c)
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 motion, where the court adopted Natural Alternatives\u8217\'3f proposed construction to evaluate patent eligibility in plaintiff\u8217\'3fs favor. Because of that, the appeal was premised under Natural Alternatives\u8217\'3f construction. On remand, however, I do not read the majority\u8217\'3fs decision as one that precludes claim construction.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00072047780027_79}{\*\bkmkend co_footnote_B00072047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00072047780027_ID0EDMCI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Likewise, for claim 6 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f376 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, the added limitation is that it \u8220\'3feffectively increases athletic performance when administered to the human over a period of time.\u8221\'3f
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00082047780027_79}{\*\bkmkend co_footnote_B00082047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00082047780027_ID0ENMCI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The majority states that it is not accurate to criticize the claims on the basis that the \u8220\'3feffective\u8221\'3f limitation does not appear in the plain language of the claims. I disagree. First, while some of the asserted claims use the word \u8220\'3feffective,\u8221\'3f not all do. Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f084 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 is independent and does not include any reference to effectiveness. The majority\u8217\'3fs citations to other claims within the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f084 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 do not detract from my basic point that \u8220\'3fdietary supplement\u8221\'3f or \u8220\'3fhuman dietary supplement\u8221\'3f do not, alone, import an effectiveness component as the proposed construction requires. Likewise, none of the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f376 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 include any reference to effectiveness. Second, if \u8220\'3fdietary supplement,\u8221\'3f as a term, included an effectiveness component, this would undermine the necessity for claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f865 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 to use the term \u8220\'3feffective.\u8221\'3f In other words, the fact that some claims use \u8220\'3feffective\u8221\'3f to reflect that limitation undercuts a construction that such limitation exists within the definition of \u8220\'3fdietary supplement\u8221\'3f or \u8220\'3fhuman dietary supplement.\u8221\'3f Lastly, even for the claims that use \u8220\'3feffective,\u8221\'3f that limitation still depends on Natural Alternatives\u8217\'3f proposed claim construction of \u8220\'3feffective\u8221\'3f as \u8220\'3felevat[ing] beta-alanine 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
above natural levels
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 to cause an increase in the synthesis of beta-alanylhistidine dipeptide in the tissue.\u8221\'3f J.A. 579\u8211\'3f81 (emphasis added).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00092047780027_79}{\*\bkmkend co_footnote_B00092047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00092047780027_ID0ERSCI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The majority contends that, through this citation, I am incorrectly suggesting that \u8220\'3fdietary supplement\u8221\'3f may not be a limitation. To be clear, that is what the District of Delaware held, and I raise that holding to underscore the complexities about the proposed construction, particularly because one of the patents at issue in the Delaware case (
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002476269&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Ib436c710728311d7ab54daa4035d65fa&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
U.S. Patent. No. 6,426,361
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
) had similar claims as those here. For example, claims 1 and 5 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002476269&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Ib436c710728311d7ab54daa4035d65fa&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f361 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 recite:
\par 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
1. A composition comprising a mixture of a creatine and a composition comprising an amino acid or an active derivative thereof selected from the group consisting of a beta-alanine, an ester of a beta-alanine and an amide of a beta-alanine.
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
....
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
5. A dietary supplement comprising a mixture of a creatine and a composition comprising an amino acid or an active derivative thereof selected from the group consisting of a beta-alanine, an ester of a beta-alanine and an amide of a beta-alanine.
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002476269&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Ib436c710728311d7ab54daa4035d65fa&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f361 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 col. 15 ll. 17\u8211\'3f21, 30\u8211\'3f34. In concluding that \u8220\'3fdietary supplement\u8221\'3f was not a limitation, the court pointed out that \u8220\'3fthe specification simply notes that the claimed \u8216\'3fcomposition 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
can be
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 a dietary supplement.\u8217\'3f \u8221\'3f 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Delaware Order
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 at 2 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002476269&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Ib436c710728311d7ab54daa4035d65fa&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f361 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 col. 3 l. 41 (emphasis in original)). The claims implicated in this case are similar to those in the 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Delaware Order
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, and the written descriptions likewise include this permissive\u8212\'3fyet non-restrictive\u8212\'3flanguage. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
E.g.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, \u8217\'3f569 patent col. 3 l. 32; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f376 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 col. 6 l. 48; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023575930&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iaa8a02cbe6d811df852cd4369a8093f1&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f084 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 col. 6 l. 52; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030875825&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I80cdc920def511e29a8295b9e0032b80&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f865 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 col. 6 l. 53; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035727267&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=Iee683580d88e11e48389be962897cf71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f610 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 col. 6 l. 54.
\par 
}
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00102047780027_79}{\*\bkmkend co_footnote_B00102047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00102047780027_ID0EJYCI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
6
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
For the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018374372&pubNum=0004074&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=PA&docFamilyGuid=I12e6e07a132211deb7e683ba170699a5&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f376 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 the construction defines \u8220\'3fdietary supplement\u8221\'3f to effectively increase athletic performance. J.A. 14 n.8.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00112047780027_79}{\*\bkmkend co_footnote_B00112047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00112047780027_ID0E1YCI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
7
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Dietary supplement
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, Merriam-Webster Unabridged, http://unabridged.merriam-webster.com/unabridged/dietarysupplement; 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006931523&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1314&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1314" }{\fldrslt 
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Phillips
}
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 415 F.3d at 1314
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (general purpose dictionaries are helpful when construction involves widely accepted meaning of commonly understood words); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2000094168&pubNum=0000506&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RP&fi=co_pp_sp_506_1334&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1334" }{\fldrslt 
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Optical Disc Corp. v. Del Mar Avionics
}
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 208 F.3d 1324, 1334\u8211\'3f
}
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf20 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (Fed. Cir. 2000)
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fWithout evidence in the patent specification of an express intent to impart an innovative meaning to a claim term, the term takes on its ordinary meaning. For such ordinary meaning, we turn to the dictionary definition of the term.\u8221\'3f (internal citations omitted)).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00122047780027_79}{\*\bkmkend co_footnote_B00122047780027_79}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00122047780027_ID0EC2CI_79" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
8
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Notably, the definitions of \u8220\'3fdietary supplement\u8221\'3f set out by the Food and Drug Administration, J.A. 590, and the Dietary Supplement Health and Education Act, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS321&originatingDoc=I35f48e50475611e98335c7ebe72735f9&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_2e4f0000f4472" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
21 U.S.C. \u167\'3f 321(ff)
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, also do not reflect a functional/effectiveness component within the meaning of the term. That is, these definitions do not support a finding that the effective increase of athletic performance or tissue function is embedded within the meaning of \u8220\'3fdietary supplement.\u8221\'3f
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf27 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf27 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf27 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf27 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf27 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf27 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf27 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf27 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }